Pharmaceutical Corruption Media Articles

Excerpts of Key Pharmaceutical Corruption Media Articles in Major Media

Below are key excerpts of revealing news articles on pharmaceutical industry corruption from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

For further exploration, delve into our comprehensive Health and Food Corruption Information Center.

Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.

Beginning in 1997, Pharmacia, currently a subsidiary of Pfizer, sought to boost its sales of the drug Genotropin. To that end, the company illegally marketed the drug to spur growth in short children and as an anti-aging drug for adults looking for the fountain of youth. In a nutshell, the off-label marketing scheme included direct payments to doctors, all-expense paid junkets for doctors, financial incentives to distributors and phony consultant contracts to funnel payments for the off-label promotion. As a result of the scheme's success, sales of the Genotropin sky-rocketed and over the years, Medicaid and other public healthcare programs paid millions of dollars for its improper use. The full amount of damage to health care programs is not yet known. "But this much is certain," former Pfizer Vice President turned whistleblower, Dr Peter Rost, says, "Pharmacia turned Genotropin into a cash cow by illegally peddling a dangerous drug to make short kids tall and their grandparents young." Genotropin is a man made human growth hormone approved to treat a limited range of hormonal deficiencies. The FDA has never approved the drug to spur growth for children without hormonal deficiencies or to prevent aging. Dr Rost joined Pharmacia in June of 2001 as a VP of Marketing. On May 22, 2003, Dr Rost became aware of the pervasive nature of ongoing illegal activity. [He then] decided to file a lawsuit ... alleging fraud relating to the off-label marketing of Genotropin and delivered a copy of the complaint to the US Attorney's Office on June 4, 2003.

Note: Read an excellent article on Dr. Rost and other major whistleblowers from the pharmaceutical industry.

Vaccine industry officials helped shape legislation behind the scenes that Senate Majority Leader Bill Frist secretly amended into a bill to shield them from lawsuits, according to e-mails obtained by a public advocacy group. E-mails and documents written by a trade group for the vaccine-makers show the organization met privately with Frist's staff and the White House about measures that would give the industry protection from lawsuits filed by people hurt by the vaccines. Frist, along with House Speaker Dennis Hastert, R-Ill., ordered the vaccine liability language inserted in a defense spending bill in December without debate and in violation of usual Senate practice. In a written statement, Frist spokeswoman Amy Call stated that the senator had promised publicly to include the vaccine liability protection in the defense spending bill. She did not address the issue of the influence of industry lobbyists.

Note: For one-paragraph summaries of media articles showing why the vaccine makers want this protection, click here.

Fraudulent research regularly appears in the 30,000 scientific journals published worldwide, a former editor of the British Medical Journal (BMJ) said today. Even when journals discover that published research is fabricated or falsified they rarely retract the findings, according to Richard Smith, who was also chief executive of the BMJ publishing group. Writing in the latest edition of the Journal of the Royal Society of Medicine, Dr Smith called on editors to blow the whistle on bad research and to use their clout to pressure universities into taking action against dodgy researchers. The former BMJ editor said it was likely that research fraud was "equally common" in the 30,000 plus scientific journals across the globe but was "invariably covered up". His call for action comes in the wake of several high profile cases of fraudulent research, including the Korean scientist Hwang Woo-suk who fabricated stem cell research that it was claimed would open up new ways to treat diseases like Parkinson's. Dr Smith criticised the failure of scientific institutions, including universities, to discipline dodgy researchers even when alerted to problems by journals. "Few countries have measures in place to ensure research is carried out ethically," he said. "Most cases are not publicised. They are simply not recognised, covered up altogether or the guilty researcher is urged to retrain, move to another institution or retire from research."

Note: For reliable information on the collusion of industry, government, and research facilities who place profits above advances in public health: http://www.WantToKnow.info/healthcoverup

Every psychiatric expert involved in writing the standard diagnostic criteria for disorders such as depression and schizophrenia has had financial ties to drug companies that sell medications for those illnesses, a new analysis has found. Of the 170 experts in all who contributed to the manual that defines disorders from personality problems to drug addiction, more than half had such ties, including 100 percent of the experts who served on work groups on mood disorders and psychotic disorders. "I don't think the public is aware of how egregious the financial ties are in the field of psychiatry," said Lisa Cosgrove, a clinical psychologist at the University of Massachusetts in Boston. The analysis comes at a time of growing debate over the rising use of medication as the primary or sole treatment for many psychiatric disorders, a trend driven in part by definitions of mental disorders in the psychiatric manual. Cosgrove said she began her research after discovering that five of six panel members studying whether certain premenstrual problems are a psychiatric disorder had ties to Eli Lilly & Co., which was seeking to market its drug Prozac to treat those symptoms. The process of defining such disorders is far from scientific, Cosgrove added: "You would be dismayed at how political the process can be."

According to reports published today...healthy people are being turned into patients by drug firms which publicise mental and sexual problems and promote little-known conditions only then to reveal the medicines they say will treat them.The studies, published in a respected medical journal, accuse the pharmaceutical industry of "disease mongering" - a practice in which the market for a drug is inflated by convincing people they are sick and in need of medical treatment. The "corporate-sponsored creation of disease" wastes resources and may even harm people because of the medication they turn to, the researchers add. In 11 papers in the journal Public Library of Science Medicine, experts from Britain, the US and elsewhere argue that new diseases are being defined by specialists who are often funded by the drug industry.According to the researchers, the campaigns boost drug sales by medicalising aspects of normal life.

Note: For more on how the pharmaceutical companies can negatively impact your health and your wallet:
http://www.WantToKnow.info/healthcoverup

Some of Britain’s leading scientists have accused the BBC of “quackery” by misleading viewers in an attempt to exaggerate the power of alternative medicine. The criticisms centre on Alternative Medicine, a series broadcast on BBC2 in January. The key critics include two scientific advisers to the series: Edzard Ernst, professor of complementary medicine at Exeter University; and George Lewith, director of the centre for the study of complementary medicine at Southampton University. Lewith, an expert on the effects of acupuncture, said in an interview yesterday: “The experiment was not groundbreaking; its results were sensationalised.” A [BBC] spokesman said yesterday: “We take these allegations very seriously and we strongly refute them. We used two scientific consultants for the series, Professor Ernst and Jack Tinker, dean emeritus of the Royal Society of Medicine, both of whom signed off the programme scripts. It seems extremely unusual that Professor Ernst should make these comments so long after the series has aired.” The spokesman said Tinker had indicated he remained happy with the tone and content of the films, stating: “Fellow medics at the Royal Society, including one eminent professor, said it was the best medical series they had seen on television.”

From 1994 to 2003, medical research funded by pharmaceutical and biotechnology companies steadily increased and now surpasses research funded by government or public sources, according to a review of the most frequently cited studies. In the new study, reported in the March 17th online issue of the British Medical Journal, the sponsorship of 289 articles...was determined. Overall, 60% of articles had government or public funding and 36% were funded by industry. However, this masks the dramatic rise in industry funding that occurred over time: in 1994, roughly 30% of articles were funded by industry compared with over 50% in 2001. Moreover, 65 of the 77 most cited randomized controlled trials involved industry funding. "Medical research should reflect public needs more closely and the efforts of all of those involved should be better coordinated," the authors emphasize.

The US Defence Secretary has made more than $5m (Ł2.9m) in capital gains from selling shares in the biotechnology firm that discovered and developed Tamiflu, the drug being bought in massive amounts by Governments to treat a possible human pandemic of the disease. More than 60 countries have so far ordered large stocks of the antiviral medication - the only oral medicine believed to be effective against the deadly H5N1 strain of the disease - to try to protect their people. The United Nations estimates that a pandemic could kill 150 million people worldwide. The drug was developed by a Californian biotech company, Gilead Sciences. Mr Rumsfeld was on the board of Gilead from 1988 to 2001, and was its chairman from 1997. He then left to join the Bush administration, but retained a huge shareholding. The 2005 report showed that, in all, he owned shares worth up to $95.9m, from which he got an income of up to $13m. The firm made a loss in 2003, the year before concern about bird flu started. Then revenues from Tamiflu almost quadrupled, to $44.6m, helping put the company well into the black. Sales almost quadrupled again, to $161.6m last year.

Note: If the above link fails, click here. With both the avian flu and swine flu, top drug companies raked in billions of dollars from sales of medications and vaccines, most of which went unused and have now expired. For many more strange coincidences and facts around the avian and swine flu scares, take a look at our summary of eye-opening news articles available here.

The prospect of a bird flu outbreak may be panicking people around the globe, but it's proving to be very good news for Defense Secretary Donald Rumsfeld and other politically connected investors in Gilead Sciences, the California biotech company that owns the rights to Tamiflu. Rumsfeld served as Gilead (Research)'s chairman from 1997 until he joined the Bush administration in 2001, and he still holds a Gilead stake valued at between $5 million and $25 million. In the past six months fears of a pandemic and the ensuing scramble for Tamiflu have sent Gilead's stock from $35 to $47. That's made the Pentagon chief, already one of the wealthiest members of the Bush cabinet, at least $1 million richer. Rumsfeld isn't the only political heavyweight benefiting from demand for Tamiflu. Former Secretary of State George Shultz, who is on Gilead's board, has sold more than $7 million worth of Gilead since the beginning of 2005.

Serono Laboratories agreed Monday to pay $704 million and plead guilty to federal conspiracy charges that it increased the market for the AIDS drug Serostim by offering kickbacks to doctors and manipulating a test for AIDS patients. Eighty-five percent of prescriptions written for Serostim, accounting for roughly $615 million in sales, were unnecessary. The cost of many of those prescriptions, $21,000 for 12 weeks of treatment, was paid by Medicaid, the joint federal-state health program for the poor, and other government insurance plans. Serono offered doctors free trips to the south of France in return for agreeing to write up to 30 new prescriptions for Serostim. The company also conspired to introduce a test for AIDS wasting, despite not having FDA approval. The test diagnosed AIDS wasting even without weight loss. Monday's settlement is the latest in a series of whistleblower claims that have resulted in more than $3 billion in payments from drug companies in recent years.

Note: For lots more on this vital topic: http://www.WantToKnow.info/healthcoverup

The pharmaceutical industry is bracing itself for criticism when the film 'The Constant Gardener' opens next month. Away from the Hollywood script is a true story of how multinational drug companies took liberties with African lives with devastating consequences. Directed by Fernando Meirelles, of City of God fame, it is a thriller, a love story and a blistering attack on the drugs industry and the way it carelessly expends the lives of innocent citizens in the Third World in the quest for billion-dollar medicines to sell to the first world. After the credits roll, a note from John Le Carré appears on screen that reads: "As my journey through the pharmaceutical jungle progressed, I came to realise that, by comparison with the reality, my story was as tame as a holiday postcard." The film features two brutal killings, a savage beating, a campaign of harassment, intimidation and threats. The crimes of the pharmaceutical industry - from the price protection of Aids drugs which have denied life-saving medicines to millions, to the cover up of lethal side effects to protect profits - are well documented. The companies are not obliged to disclose a lot of information about how they test or make their drugs. There's big, big money involved. Editors of medical journals including The Lancet and The Journal of the American Medical Association had come under pressure not to publish data or to change it. The bigger scandal...lies in the rapacious pricing of the pharmaceutical industry that puts lifesaving drugs out of reach of individuals, hospitals and even nations.

No single person has come to more represent the big questions about drug safety that emerged following the withdrawal of Merck's painkiller Vioxx than the Food and Drug Administration's David Graham. And now that a Texas jury has awarded the widow of one Vioxx patient $253 million, Graham, who works in the FDA's Office of Drug Safety, is more critical than ever. Of the drug, and his employer, for whom he doesn't speak. "If the judgment is that there's blood on Merck's hands," Graham says, "there's blood on the FDA's hands as well." Graham has estimated that Vioxx killed some 60,000 patients - as many people, he points out, as died in the Vietnam War. He says that fundamental problems at the FDA led to those deaths. "People should turn to Congress and demand a drug safety system that is free from corporate influence - and a distinct center for drug safety." In Graham's eyes, the problem at the FDA is that the same scientists who approve drugs are the ones charged with deciding whether or not they are safe enough to remain on the market when problems crop up. Graham says that he thinks there should be formal, periodic reviews of the safety of new medicines - and that the FDA should release documents that explain its reasoning. "The FDA does not think anything it did is a mistake," he says. "[Yet] none of its decisions are evidence-based." "Today Merck was on trial, and a judgment was rendered," he says. "But when will the public hold the FDA accountable for its role, its complicity, in this catastrophe?"

Note: Learn how Merck blatantly altered the death numbers in their drug trials in this Seattle Times article. This article persuasively argues the actual death numbers were around 500,000. WTK founder Fred Burks had a shocking encounter where he learned about intense corruption at the FDA. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.

The maker of a billion-dollar antipsychotic medication has acknowledged misleading doctors and other healthcare providers about the safety of its product, minimizing potentially deadly side effects. On Wednesday, drug maker Janssen Pharmaceutica wrote a two-page letter to doctors, warning them that the company, in promotional material, had "minimized potentially fatal risks, and made misleading claims" that the medication was more safe in treating mental illness than other drugs in the same category. Risperdal is the leading drug used to combat schizophrenia and other types of psychotic disorders, earning Janssen about $2.1 billion in annual sales. The drug was first marketed about eight years ago, and is prescribed to more than 10 million people worldwide. The "important correction of drug information" came shortly after federal regulators had accused Janssen of "disseminating" advertising and marketing material that was "false or misleading."

Don't miss the highly revealing article on this vital topic by the New England Journal of Medicine's former editor in chief Marica Angell. Click here

Doctors accused of making up data in medical studies. Allegations of misconduct by U.S. researchers reached record highs last year as the Department of Health and Human Services received 274 complaints - 50 percent higher than 2003 and the most since 1989 when the federal government established a program to deal with scientific misconduct. Chris Pascal, director of the federal Office of Research Integrity, said its 28 staffers and $7 million annual budget haven't kept pace with the allegations. The result: Only 23 cases were closed last year. Of those, eight individuals were found guilty of research misconduct. In the past 15 years, the office has confirmed about 185 cases of scientific misconduct. Research suggests this is but a small fraction of all the incidents of fabrication, falsification and plagiarism. In a survey published June 9 in the journal Nature, about 1.5 percent of 3,247 researchers who responded admitted to falsification or plagiarism. (One in three admitted to some type of professional misbehavior.)

Despite calls for more transparency after revelations about the side effects of ibuprofen, the FDA has withheld 28 pages of information on a new wave of painkillers. Vital data on prescription medicines found in millions of British homes has been suppressed by the powerful US drug regulators, even though the information could potentially save lives. An investigation by The Independent on Sunday shows that, under pressure from the pharmaceutical industry, the American Food and Drug Administration routinely conceals information it considers commercially sensitive, leaving medical specialists unable to assess the true risks. Dr Peter Juni, one of the team of Swiss investigators who helped to expose the risk of the new-generation drugs, claims his efforts were obstructed by the FDA. "Too often the FDA saw and continues to see the pharmaceutical industry as its customers, a vital source of funding for its activities, and not as a sector of society in need of strong regulation."

When the drug industry came under fire last summer for failing to disclose poor results from studies of antidepressants, major drug makers promised to provide more information about their research on new medicines. But nearly a year later, crucial facts about many clinical trials remain hidden. Eli Lilly and some other companies have posted hundreds of trial results on the Web and pledged to disclose all results for all drugs they sell. But other drug makers, including Merck and Pfizer, release less information and are reluctant to add more, citing competitive pressures. As a result, doctors and patients lack critical information about important drugs ... and the companies can hide negative trial results by refusing to publish studies, or by cherry-picking and highlighting the most favorable data. GlaxoSmithKline agreed to pay $2.5 million to settle a suit ... alleging that Glaxo had hidden results from trials showing that its antidepressant Paxil might increase suicidal thoughts in children and teenagers. Federal laws require the disclosure of all trials and trial results to the F.D.A. But companies are not required to disclose trial results to scientists or the public. Under pressure from the editors of medical journals, the major drug companies in January agreed to expand the number of trials registered on clinicaltrials.gov. Three companies have filed only vague descriptions of many studies, often failing even to name the drugs under investigation. For example, Merck describes one trial as a "one-year study of an investigational drug in obese patients."

Merck & Co.'s longtime leader Raymond V. Gilmartin abruptly resigned yesterday on the same day congressional investigators released a slew of documents detailing how the company continued to aggressively promote its arthritis drug Vioxx after it knew of potentially serious safety concerns. The documents...showed that Merck directed its 3,000-person Vioxx sales force to avoid discussions with doctors about the cardiovascular risks identified in a major clinical trial of the drug in 2000. Sales representatives were told instead to rely on a "Cardiovascular Card" that said Vioxx was protecting the heart rather than potentially harming it. They were [also] trained how to smile, speak and position themselves most effectively when talking with doctors, and were exhorted to sell Vioxx and other Merck drugs using the Rev. Martin Luther King Jr.'s "I Have a Dream" speech. Vioxx was withdrawn from the market last September after another clinical trial found that people who had taken the drug for 18 months were five times more likely to have heart attacks and strokes than those on a placebo. Merck was sharply criticized in a hearing into how the company and the Food and Drug Administration had handled the safety concerns surrounding Vioxx.

During a nine month investigation, the BBC has uncovered the disturbing truth about the way authorities in New York City are conducting the fight against Aids. HIV positive children - some only a few months old - are enrolled in toxic experiments without the consent of guardians or relatives. In some cases where parents have refused to give children their medication, they have been placed in care. The city's Administration of Children's Services (ACS) does not even require a court order to place HIV kids with foster parents or in children's homes, where they can continue to give them experimental drugs. In 2002, the Incarnation Children's Center - a children's home in Harlem - was at the hub of controversy over secretive drugs trials. [Reporter Jamie Doran] speaks to a boy who spent most of his life at Incaranation. Medical records, obtained by the This World team, prove the boy had been enrolled in these trials. "I did not want to take my medication," said the boy, "but if you want to get out of there, you have to do what they say." He also conveys a horrifying account of what happened to the children at Incarnation who refused to obey the rules. "My friend Daniel didn't like to take his medicine and he got a tube in his stomach," he said. For months, the BBC tried to get information from the people responsible for the trials, but none would comment. The companies that supply drugs for the trials are among the world's largest, including Britain's own Glaxo SmithKline (GSK).

Note: Read a long list of examples of humans being treated as guinea pigs by corporate and governmental programs. For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in Big Pharma from reliable major media sources.

No one foresaw ... the shocking extent to which the internet would change the terms of trade between corporations and society. One of the world's largest drug companies [was] the first victim. Britain's GlaxoSmithKline, the world's second-largest pharma, denied any wrongdoing, but agreed to pay $2.5m ... for concealing evidence of its antidepressant Seroxat's potential for harming children, while doing them no measurable good. Infinitely more frightening ... this pharma had the backing of institutions that we, the public, rely on to protect us from poisoning by prescription. The Royal College of Psychiatrists had insisted only a year earlier that 'there is no evidence that antidepressant drugs can cause dependence syndromes'. It was really the internet that allowed public health activists to do an end run around GSK's and the medical authorities' denials of the drug's risks. An explosion of websites dedicated to vivid accounts of antidepressant reactions told these campaigners about hundreds of thousands affected by a problem that officially did not exist. Health activists in Britain and America have uncovered the core of pharma might. In both countries, clinical drug tests are paid for by the pharmas, who tweak the trials' design for the best possible results. Until recently, only the most favourable findings got published in the 20,000-odd biomedical journals, many of them dependent on pharmas for funding. The drugs are approved for marketing by regulators, whose salaries are mostly financed by the subjects of their evaluations. The medicines are then prescribed by doctors routinely courted with pharma gifts ... meant to persuade them to change their prescribing habits.

Note: For a two-page summary with lots more reliable information on major health cover-ups by a doctor who was editor-in-chief of one of the most pretigious medical journals in the world, click here.

Dr. Marcia Angell is a former editor in chief of The New England Journal of Medicine and spent two decades on the staff of that publication. Her new book is a scorching indictment of drug companies and their research and business practices. "Despite all its excesses, this is an important industry that should be saved - mainly from itself," she writes. Dr. Angell's case is tough, persuasive and troubling. "The Truth About the Drug Companies" ... is devoted to assertions of shady, misleading corporate behavior. In the past, drug discoveries made through government research remained in the public domain. Beginning in 1980 those breakthroughs could be patented, even if their research was sponsored by the National Institutes of Health. As a consequence, Dr. Angell says, patent shenanigans have reshaped the drug business, as have the recent government regulations that expedite direct-to-consumer drug advertising. "Once upon a time, drug companies promoted drugs to treat diseases," Dr. Angell writes. "Now it is often the opposite. They promote diseases to fit their drugs." Why all the advertising? "If prescription drugs are so good, why do they need to be pushed so hard?" she asks. Dr. Angell is now a senior lecturer at Harvard Medical School.

Note: For an excellent 10-page summary of this revealing book written by the esteemed author, click here. For more reliable information on the health cover-up, click here.

Important Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.